Literature DB >> 18094668

Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.

Juan R Bustillo1, Laura M Rowland, Rex Jung, William M Brooks, Clifford Qualls, Roger Hammond, Blaine Hart, John Lauriello.   

Abstract

Reduced brain N-acetyl-aspartate (NAA) has been repeatedly found in chronic schizophrenia and suggests neuronal loss or dysfunction. However, the potential confounding effect of antipsychotic drugs on NAA has not been resolved. We studied 32 minimally treated schizophrenia patients and 21 healthy subjects with single-voxel proton magnetic resonance spectroscopy ((1)H-MRS) of the frontal and occipital lobes, caudate nucleus, and cerebellum. Concentrations of NAA, Choline, and Cre were determined and corrected for the proportion of cerebrospinal fluid (CSF) in the voxel. Patients were treated in a randomized-controlled double-blind manner with either haloperidol or quetiapine. (1)H-MRS was repeated every 6 months for up to 2 years. There was a group main effect for baseline NAA with lower global NAA in schizophrenia subjects before treatment compared to healthy controls. Global NAA was directly related to measures of global cognitive performance in the whole subject sample. Following treatment with haloperidol or quetiapine, there were no changes in NAA in any of the regions studied. Early in the illness, schizophrenia patients already demonstrate subtle reductions in NAA. Treatment with typical or atypical antipsychotic medications for several months does not result in NAA changes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094668     DOI: 10.1038/sj.npp.1301631

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  30 in total

1.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

2.  Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1)H-MRS study.

Authors:  Mark S Brown; Debra Singel; Susan Hepburn; Donald C Rojas
Journal:  Autism Res       Date:  2012-11-16       Impact factor: 5.216

Review 3.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

4.  Using longitudinal imaging to map the 'relapse signature' of schizophrenia and other psychoses.

Authors:  V L Cropley; C Pantelis
Journal:  Epidemiol Psychiatr Sci       Date:  2014-05-22       Impact factor: 6.892

5.  Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

Authors:  Meredith A Reid; Luke E Stoeckel; David M White; Kathy B Avsar; Mark S Bolding; N Shastry Akella; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2010-06-08       Impact factor: 13.382

6.  A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia.

Authors:  Nina V Kraguljac; Charity J Morgan; Meredith A Reid; David M White; Ripu D Jindal; Soumya Sivaraman; Bridgette K Martinak; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2019-01-07       Impact factor: 4.939

7.  Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression.

Authors:  Kiki Chang; Melissa Delbello; Wen-Jang Chu; Amy Garrett; Ryan Kelley; Neil Mills; Meghan Howe; Holly Bryan; Cal Adler; Jim Eliassen; Daniel Spielman; Stephen M Strakowski
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-07-31       Impact factor: 2.576

8.  Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.

Authors:  Eric Plitman; Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Sofia Chavez; Gladys Gómez-Cruz; Pablo León-Ortiz; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2015-08-28       Impact factor: 9.306

9.  Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia.

Authors:  Meredith A Reid; Nina V Kraguljac; Kathy B Avsar; David M White; Jan A den Hollander; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2013-05-21       Impact factor: 4.939

10.  Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Camilo de la Fuente-Sandoval; Pablo León-Ortiz; Mariana Azcárraga; Sylvana Stephano; Rafael Favila; Leonardo Díaz-Galvis; Patricia Alvarado-Alanis; Jesús Ramírez-Bermúdez; Ariel Graff-Guerrero
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.